Literature DB >> 2431019

Antinuclear antibodies in primary pulmonary hypertension.

S Rich, K Kieras, K Hart, B M Groves, J D Stobo, B H Brundage.   

Abstract

The association of positive antinuclear antibodies with the clinical and hemodynamic features of 43 patients with primary pulmonary hypertension and 16 patients with secondary pulmonary hypertension was investigated. Each patient had determinations of antinuclear antibodies using a KB cell substrate immunofluorescent test. Of the patients with primary pulmonary hypertension, 40% had positive antinuclear antibodies at titers of 1:80 dilutions or greater. There were no differences between patients with primary pulmonary hypertension and positive antinuclear antibodies compared with those with negative antinuclear antibodies in relation to clinical or hemodynamic status. A 6% incidence rate of antinuclear antibodies was found in patients with secondary pulmonary hypertension, similar to that in the normal population. The clinical, hemodynamic, serologic and histologic similarity between patients with primary pulmonary hypertension and those with unexplained pulmonary hypertension associated with collagen vascular disorders suggests that primary pulmonary hypertension in some patients may represent a collagen vascular disease confined to the lungs. The frequency of positive antinuclear antibody tests would place primary pulmonary hypertension between rheumatoid arthritis and scleroderma in the spectrum of collagen vascular diseases. Further studies are necessary, however, before one might expect that immunosuppressive therapy would be beneficial to these patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431019     DOI: 10.1016/s0735-1097(86)80301-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  25 in total

1.  Recovery from pulmonary hypertension in an adolescent with mixed connective tissue disease.

Authors:  D M Friedman; H J Mitnick; D Danilowicz
Journal:  Ann Rheum Dis       Date:  1992-08       Impact factor: 19.103

Review 2.  Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension.

Authors:  Marjorie Barrier; Jolyane Meloche; Maria Helena Jacob; Audrey Courboulin; Steeve Provencher; Sébastien Bonnet
Journal:  Cell Mol Life Sci       Date:  2012-03-25       Impact factor: 9.261

Review 3.  The antiphospholipid syndrome: a syndrome in evolution.

Authors:  R A Asherson; R Cervera
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

Review 4.  Pulmonary hypertension, antiphospholipid antibodies, and syndromes.

Authors:  Ronald A Asherson; Ricard Cervera
Journal:  Clin Rev Allergy Immunol       Date:  2007-04       Impact factor: 8.667

5.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

Review 6.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

8.  The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension.

Authors:  Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Respir Crit Care Med       Date:  2017-05-15       Impact factor: 21.405

Review 9.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

10.  Key inflammatory pathways underlying vascular remodeling in pulmonary hypertension.

Authors:  E M Berghausen; L Feik; M Zierden; M Vantler; S Rosenkranz
Journal:  Herz       Date:  2019-04       Impact factor: 1.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.